For very low birth-weight (VLBW) infants, transcatheter closure of the patent ductus arteriosus (PDA) is increasingly used, with selected short-term outcomes slightly more favorable, according to a ...

In a clinical report published in the May issue of Pediatrics, the American Academy of Pediatrics presents updated guidance on the evaluation and treatment of patent ductus arteriosus (PDA) in preterm ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

In 2019, the U.S. Food and Drug Administration approved the first PDA occlusion device for infants as small as 700 grams, leading to rapid adoption of tcPDA in premature infants. Catheter-based ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.